Pharmaceutical Product Development, Inc. 

(Public, NASDAQ:PPDI)   Watch this stock   
Find more results for PPDI
Jan 26, 2010
Jefferies Global Healthcare Services Conference
Jan 20, 2010
2010 Financial Guidance Announcement
Jan 20, 2010
Q4 2009 Earnings Conference Call
Jan 19, 2010
Q4 2009 Earnings Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 11.05% 11.94%
Operating margin 13.75% 16.82%
EBITD margin - 20.67%
Return on average assets 7.90% 10.91%
Return on average equity 11.44% 16.09%
Employees 10,500 -

Address

929 North Front Street
Wilmington, NC 28401
United States - Map
+1-910-2510081 (Phone)
+1-910-5587056 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Pharmaceutical Product Development, Inc. discussed on blogs

Pharmaceutical Product Development, Inc. discussions

  View all discussions »

Description

Pharmaceutical Product Development, Inc. is a global contract research organization engaged in providing drug discovery and development services, post-approval expertise and compound partnering programs. The Company’s customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. It operates in two segments: Discovery Sciences and Development. The Discovery Sciences Group focuses on the discovery research segment of the biopharmaceutical research and development outsourcing market. The Development Group provides a range of development services, either individually or as an integrated package. In April 2009, the Company acquired Magen BioSciences, Inc. In April 2009, the Company completed the acquisition of AbC.R.O., Inc. (AbCRO). In November 2009, the Company completed its acquisition of Excel PharmaStudies, Inc. In November 2009, the Company completed the acquisition of BioDuro LLC.

Officers and directors

Fredric N. Eshelman
Executive Chairman of the Board
Age: 60
Bio & Compensation - Reuters
David L. Grange
Chief Executive Officer, Director
Age: 60
Bio & Compensation - Reuters
Daniel G. Darazsdi
Chief Financial Officer, Treasurer, Assistant Secretary
Age: 48
Bio & Compensation - Reuters
William J. Sharbaugh
Chief Operating Officer
Age: 46
Bio & Compensation - Reuters
Mike Wilkinson
Executive Vice President - Global Clinical Development
Age: 54
Bio & Compensation - Reuters
Christine A. Dingivan M.D.
Executive Vice President, Chief Medical Officer
Age: 41
Bio & Compensation - Reuters
William W. Richardson
Senior Vice President - Global Business Development
Age: 56
Bio & Compensation - Reuters
Ernest Mario Ph.D.
Lead Independent Director
Age: 70
Bio & Compensation - Reuters
Stuart Bondurant
Director
Age: 78
Bio & Compensation - Reuters
Frederick Frank
Director
Age: 77
Bio & Compensation - Reuters